Furosemide Loaded Silica-Lipid Hybrid Microparticles: Formulation Development, in vitro and ex vivo Evaluation

Swapna Sambaraj ¹, Divya Ammula ², Vijaykumar Nagabandi ² *

Cited by CrossRef: 7

1- Mohapatra S, Bindhani S, Kar R, Pani N, Nayak A. Preparation and evaluation of solid self-microemulsifying drug delivery system of eprosartan mesylate using vegetable oils. Journal of Drug Delivery Science and Technology. 2021;66:102771 [Crossref]

2- Ghadi R, Dand N. BCS class IV drugs: Highly notorious candidates for formulation development. Journal of Controlled Release. 2017;248:71 [Crossref]

3- Meka A, Jenkins L, Dàvalos-Salas M, Pujara N, Wong K, Kumeria T, Mariadason J, Popat A. Enhanced Solubility, Permeability and Anticancer Activity of Vorinostat Using Tailored Mesoporous Silica Nanoparticles. Pharmaceutics. 2018;10(4):283 [Crossref]

4- Vlachou M, Siamidi A, Dotsikas Y. Utilization of a Single Experimental Design for the Optimization of Furosemide Modified-Release Tablet Formulations. CDD. 2019;16(10):931 [Crossref]

5- Diab R, Canilho N, Pavel I, Haffner F, Girardon M, Pasc A. Silica-based systems for oral delivery of drugs, macromolecules and cells. Advances in Colloid and Interface Science. 2017;249:346 [Crossref]

6- Vlachou M, Geraniou E, Siamidi A. Modified release of furosemide from Eudragits® and poly(ethylene oxide)-based matrices and dry-coated tablets. 2020;70(1):49 [Crossref]